A Safe Bacterial Microsyringe for In Vivo Antigen Delivery and Immunotherapy - Institut Albert Bonniot Accéder directement au contenu
Article Dans Une Revue Molecular Therapy Année : 2013

A Safe Bacterial Microsyringe for In Vivo Antigen Delivery and Immunotherapy

Résumé

The industrial development of active immunotherapy based on live-attenuated bacterial vectors has matured. We developed a microsyringe for antigen delivery based on the type III secretion system (T3SS) of P. aeruginosa. We applied the "killed but metabolically active" (KBMA) attenuation strategy to make this bacterial vector suitable for human use. We demonstrate that attenuated P. aeruginosa has the potential to deliver antigens to human antigen-presenting cells in vitro via T3SS with considerable attenuated cytotoxicity as compared with the wild-type vector. In a mouse model of cancer, we demonstrate that this KBMA strain, which cannot replicate in its host, efficiently disseminates into lymphoid organs and delivers its heterologous antigen. The attenuated strain effectively induces a cellular immune response to the cancerous cells while lowering the systemic inflammatory response. Hence, a KBMA P. aeruginosa microsyringe is an efficient and safe tool for in vivo antigen delivery.

Dates et versions

hal-00813378 , version 1 (15-04-2013)

Identifiants

Citer

Audrey Le Gouellec, Xavier Chauchet, David Laurin, Caroline Aspord, Julien Verove, et al.. A Safe Bacterial Microsyringe for In Vivo Antigen Delivery and Immunotherapy. Molecular Therapy, 2013, 21 (5), pp.1076-1086. ⟨10.1038/mt.2013.41⟩. ⟨hal-00813378⟩
1372 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More